TNGX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Tango Therapeutics to present updated data on vopimetostat combined with a RAS(ON) inhibitor at the 2026 ESMO CongressOct 16, 2026
- Tango reported a 92% objective response rate with the combination of Vopimetostat and Daraxonrasib in pancreatic cancerJun 8, 2026
- Tango Therapeutics reports positive data from ongoing Phase 1/2 study with Vopimetostat (TNG462) in patients with MTAP-deleted cancersOct 23, 2025
- Tango Therapeutics to present first clinical data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025Oct 6, 2025
- Tango Therapeutics doses first patient in Phase 1/2 trial of TNG462 plus Daraxonrasib or Zoldonrasib for RAS-mutant MTAP-deleted pancreatic or lung cancerJun 29, 2025